190 related articles for article (PubMed ID: 33482599)
1. A theranostic probe of indoleamine 2,3-dioxygenase 1 (IDO1) for small molecule cancer immunotherapy.
Wu Y; Zhang Y; Chen X; Hu Y; Dong G; Guo Y; Sheng C
Eur J Med Chem; 2021 Mar; 213():113163. PubMed ID: 33482599
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis and Biological Evaluation of Novel 1,2,5-Oxadiazol-3- Carboximidamide Derivatives as Indoleamine 2, 3-Dioxygenase 1 (IDO1) Inhibitors.
Xia Z; Nan Y; Liu C; Lin G; Gu K; Chen C; Zhao W; Ju D; Dong X
Anticancer Agents Med Chem; 2020; 20(13):1592-1603. PubMed ID: 32496990
[TBL] [Abstract][Full Text] [Related]
3. Discovery of IDO1 and DNA dual targeting antitumor agents.
Fang K; Wu S; Dong G; Wu Y; Chen S; Liu J; Wang W; Sheng C
Org Biomol Chem; 2017 Dec; 15(47):9992-9995. PubMed ID: 29177308
[TBL] [Abstract][Full Text] [Related]
4. Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy.
Weng T; Qiu X; Wang J; Li Z; Bian J
Eur J Med Chem; 2018 Jan; 143():656-669. PubMed ID: 29220788
[TBL] [Abstract][Full Text] [Related]
5. Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective.
Feng X; Liao D; Liu D; Ping A; Li Z; Bian J
J Med Chem; 2020 Dec; 63(24):15115-15139. PubMed ID: 33215494
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and structure-activity relationship study of novel naphthoindolizine and indolizinoquinoline-5,12-dione derivatives as IDO1 inhibitors.
Yang R; Chen Y; Pan L; Yang Y; Zheng Q; Hu Y; Wang Y; Zhang L; Sun Y; Li Z; Meng X
Bioorg Med Chem; 2018 Sep; 26(17):4886-4897. PubMed ID: 30170925
[TBL] [Abstract][Full Text] [Related]
7. Discovery of the First Potent IDO1/IDO2 Dual Inhibitors: A Promising Strategy for Cancer Immunotherapy.
He X; He G; Chu Z; Wu H; Wang J; Ge Y; Shen H; Zhang S; Shan J; Peng K; Wei Z; Zou Y; Xu Y; Zhu Q
J Med Chem; 2021 Dec; 64(24):17950-17968. PubMed ID: 34854662
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel hydroxyamidine derivatives as indoleamine 2,3-dioxygenase 1 inhibitors with in vivo anti-tumor efficacy.
Liu C; Nan Y; Xia Z; Gu K; Chen C; Dong X; Ju D; Zhao W
Bioorg Med Chem Lett; 2020 Apr; 30(8):127038. PubMed ID: 32088128
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel IDO1 inhibitors via structure-based virtual screening and biological assays.
Ge H; Mao L; Zhao J; Wang Y; Shi D; Yang X; Wang X; Liu H; Yao X
J Comput Aided Mol Des; 2021 May; 35(5):679-694. PubMed ID: 33905074
[TBL] [Abstract][Full Text] [Related]
10. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy.
Tang K; Wang B; Yu B; Liu HM
Eur J Med Chem; 2022 Jan; 227():113967. PubMed ID: 34752953
[TBL] [Abstract][Full Text] [Related]
11. A Series of 2-((1-Phenyl-1H-imidazol-5-yl)methyl)-1H-indoles as Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Zheng Y; Stafford PM; Stover KR; Mohan DC; Gupta M; Keske EC; Schiavini P; Villar L; Wu F; Kreft A; Thomas K; Raaphorst E; Pasangulapati JP; Alla SR; Sharma S; Mittapalli RR; Sagamanova I; Johnson SL; Reed MA; Weaver DF
ChemMedChem; 2021 Jul; 16(14):2195-2205. PubMed ID: 33759400
[TBL] [Abstract][Full Text] [Related]
12. 4,6-Substituted-1H-Indazoles as potent IDO1/TDO dual inhibitors.
Yang L; Chen Y; He J; Njoya EM; Chen J; Liu S; Xie C; Huang W; Wang F; Wang Z; Li Y; Qian S
Bioorg Med Chem; 2019 Mar; 27(6):1087-1098. PubMed ID: 30773421
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Molecular Modeling Studies of N'-Hydroxyindazolecarboximidamides as Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Lee DH; Lee JY; Jeong J; Kim M; Lee KW; Jang E; Ahn S; Lee CH; Hwang JY
Molecules; 2017 Nov; 22(11):. PubMed ID: 29120388
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of a novel indoleamine 2,3-dioxigenase 1 (IDO1) and thioredoxin reductase (TrxR) dual inhibitor.
Fan QZ; Zhou J; Zhu YB; He LJ; Miao DD; Zhang SP; Liu XP; Zhang C
Bioorg Chem; 2020 Dec; 105():104401. PubMed ID: 33113415
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of exiguamine A analogues as IDO1 inhibitors.
Dong J; Pan X; Yang Y; Zhang G; Xiao Z; Liu Z
Eur J Med Chem; 2021 Nov; 223():113631. PubMed ID: 34147748
[TBL] [Abstract][Full Text] [Related]
16. Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1).
Fung SP; Wang H; Tomek P; Squire CJ; Flanagan JU; Palmer BD; Bridewell DJ; Tijono SM; Jamie JF; Ching LM
Bioorg Med Chem; 2013 Dec; 21(24):7595-603. PubMed ID: 24262887
[TBL] [Abstract][Full Text] [Related]
17. Spiro-Oxindole Skeleton Compounds Are Efficient Inhibitors for Indoleamine 2,3-Dioxygenase 1: An Attractive Target for Tumor Immunotherapy.
Yan D; Xu J; Wang X; Zhang J; Zhao G; Lin Y; Tan X
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563059
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel IDO1 inhibitors targeting the protein's apo form through scaffold hopping from holo-IDO1 inhibitor.
Wu Y; Duan Q; Zou Y; Zhu Q; Xu Y
Bioorg Med Chem Lett; 2021 Nov; 52():128373. PubMed ID: 34560264
[TBL] [Abstract][Full Text] [Related]
19. Discovery of phosphonamidate IDO1 inhibitors for the treatment of non-small cell lung cancer.
Du Q; Feng X; Wang Y; Xu X; Zhang Y; Qu X; Li Z; Bian J
Eur J Med Chem; 2019 Nov; 182():111629. PubMed ID: 31445231
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and antitumor study of a series of N-Cyclic sulfamoylaminoethyl substituted 1,2,5-oxadiazol-3-amines as new indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors.
Chen S; Guo W; Liu X; Sun P; Wang Y; Ding C; Meng L; Zhang A
Eur J Med Chem; 2019 Oct; 179():38-55. PubMed ID: 31233921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
